Last reviewed · How we verify
Long-term ON-Q
Long-term ON-Q is a Small molecule drug developed by AdventHealth. It is currently in Phase 1 development.
Long-term ON-Q is an oligonucleotide modality used in various medical conditions, including Vaginal Vault Prolapse, Osteoporosis, and Prostate Cancer, as well as in nursing education and hemodialysis. It has been studied in clinical trials, including a long-term follow-up study on laparoscopic sacrocolpopexy, and has been used in examinations and nursing education interventions.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Long-term ON-Q |
|---|---|
| Sponsor | AdventHealth |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Data Quality of National Quality Indicators in Long-term Care Facilities: a Validation and Evaluation Study (NA)
- Testing the Implementation of a Toolbox to Optimize Data Collection and Data Quality of the National Medical Quality Indicators in Long-term Care Facilities: A Pilot Study. (NIP-Q-UPGRADE Subaim 1.8) (NA)
- Comparative Study on the Short- and Long-term Efficacy of Q-ISR, Traditional Sub-ISR, and t-ISR (PHASE2)
- Phosphorus Education and Adherence in Hemodialysis Patients (NA)
- Training and Support Programme on Data-driven Quality Development for Swiss Long-Term Care Facilities (NIP-Q-UPGRADE Subaim 2.6) (NA)
- Parental Stress and Attachment in Preterm Infants
- Long Term Function Outcomes and Pain in Implant-based Post-mastectomy Breast Reconstruction
- Diabetic Autonomic Neuropathy and Left Ventricular Function (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Long-term ON-Q CI brief — competitive landscape report
- Long-term ON-Q updates RSS · CI watch RSS
- AdventHealth portfolio CI
Frequently asked questions about Long-term ON-Q
What is Long-term ON-Q?
Who makes Long-term ON-Q?
What development phase is Long-term ON-Q in?
Related
- Manufacturer: AdventHealth — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing